emerg
viral
diseas
pose
uniqu
risk
public
health
thu
need
develop
therapi
current
focu
fund
agenc
henc
research
develop
broadspectrum
antivir
particular
target
common
cellular
pathway
scope
articl
review
screen
strategi
recent
advanc
area
particular
emphasi
antivir
target
step
viral
entri
emerg
lipidenvelop
virus
ebola
viru
sarscoronaviru
threat
pose
emerg
virus
review
author
discuss
number
potenti
avenu
research
meet
challeng
well
highlight
excit
new
inhibitor
variou
stage
entri
sever
emerg
virus
viral
life
cycl
present
numer
potenti
target
antivir
intervent
viral
enzym
polymeras
proteas
repres
canon
target
therapeut
neglect
viral
entri
pathway
also
repres
promis
emerg
target
antivir
mani
antivir
hiv
test
ground
number
concept
hand
new
drug
market
undergo
trial
target
differ
step
viral
entri
target
includ
attach
coreceptor
bind
viruscel
fusion
addit
entri
inhibitor
could
play
particularli
excit
role
topic
microbicid
prevent
viru
transmiss
individu
exampl
sexual
transmiss
inhibitor
viral
entri
like
provid
ration
basi
antivir
particularli
one
use
prophylact
situat
block
first
step
viral
replic
potenti
less
toxic
membran
permeabl
may
necessari
although
practic
properti
also
probabl
requir
effect
oral
avail
drug
howev
predomin
reason
entri
inhibitor
begun
appear
emerg
virus
may
due
fact
mani
pathogen
requir
high
level
biocontain
thu
surrog
assay
develop
perform
highthroughput
screen
ht
includ
use
pseudotyp
cellcel
fusion
focu
entri
process
requir
lower
level
contain
viral
entri
often
multiplestep
process
involv
complic
viralhost
interact
serv
target
inhibitor
target
includ
use
common
cellular
compon
lipid
lipid
raft
cellular
function
endocytosi
review
step
entri
step
may
target
inhibitor
tabl
particular
refer
potenti
broadspectrum
inhibitor
capabl
block
member
multipl
viru
famili
develop
ht
assay
specif
search
inhibitor
viral
entri
biggest
factor
recent
develop
candid
antivir
target
entri
emerg
virus
glycoprotein
emerg
virus
use
pseudotyp
onto
retrovir
lentivir
rhabdovir
pseudotyp
system
assay
incorpor
envelop
glycoprotein
test
viru
onto
core
report
viru
hiv
manner
infect
direct
way
authent
viru
typic
singl
round
infect
occur
infect
detect
use
enzymat
fluoresc
readout
multipl
round
infect
desir
order
fulli
test
efficaci
inhibitor
block
entri
target
cell
express
relev
viral
envelop
use
rhabdoviru
vector
allow
multipl
round
infect
method
rel
easili
adapt
ht
order
screen
inhibitor
step
viral
entri
mediat
viral
glycoprotein
pseudotyp
strategi
begin
pay
dividend
mani
emerg
virus
term
identifi
inhibitor
viral
entri
exampl
method
use
identifi
smallmolecul
inhibitor
hcv
entri
block
somewher
attach
requir
endosom
acidif
addit
second
potenti
third
pseudotyp
differ
report
system
screen
add
extra
dimens
standard
ht
allow
two
differ
envelop
screen
one
time
assay
term
dual
envelop
pseudovirion
assay
save
cost
term
labor
materi
also
afford
possibl
pseudotyp
act
intern
control
specif
inhibitor
goal
altern
broadspectrum
inhibitor
sought
deliber
diverg
envelop
pseudotyp
system
chosen
order
identifi
inhibitor
multipl
system
altern
pseudotyp
cellcel
fusion
assay
driven
surfac
express
glycoprotein
specif
fluoresc
enzymat
entri
assay
base
viruslik
particl
use
potenti
reduc
nonspecif
hit
direct
postentri
step
pseudotyp
infect
cycl
entri
begin
rel
nonspecif
interact
viru
attach
factor
cell
surfac
usual
follow
engag
specif
cellular
receptor
howev
attach
factor
may
possibl
suffici
direct
virus
flaviand
alphavirus
strong
requir
acid
ph
trigger
envelop
protein
endosom
without
engag
specif
receptor
similarli
ebov
endosom
rather
cell
surfac
appear
site
specif
receptor
engag
thu
may
rel
nonspecif
attach
factor
unlik
receptor
trigger
chang
viral
glycoprotein
main
method
target
virus
exampl
attach
factor
calciumdepend
lectin
may
help
direct
mani
virus
import
target
organ
cell
type
liver
lung
monocytemacrophag
via
engag
carbohydr
moieti
viral
glycoprotein
author
also
recent
demonstr
like
mani
virus
ebov
reli
interact
glycosaminoglycan
chain
proteoglycan
effici
initi
contact
cell
salvador
b
simmon
g
unpublish
data
interfer
viral
interact
attach
factor
would
probabl
disrupt
effici
infect
thu
step
entri
repres
good
target
inhibit
howev
mani
interact
carbohydr
lectin
chargebas
glycosaminoglycan
gag
therefor
inhibitor
may
rel
nonspecif
thu
run
risk
harm
offtarget
interact
number
molecul
abl
inhibit
interact
gag
identifi
includ
use
solubl
polysaccharid
heparin
potenti
microbicid
carrageenan
smallmolecul
inhibitor
gag
interact
surfen
well
sever
peptidebas
inhibitor
also
identifi
antivir
predominantli
suggest
topic
microbicid
could
act
model
broadspectrum
antivir
emerg
virus
cyanovirinn
cvn
natur
occur
lectin
inhibit
attach
hiv
bind
nlink
highmannos
oligosaccharid
viral
glycoprotein
current
preclin
develop
topic
microbicid
recent
cvn
found
bind
ebov
viral
surfac
glycoprotein
gp
inhibit
infect
vitro
bind
assay
mous
model
like
mode
action
involv
simpli
bind
highmannos
moieti
cell
surfac
lectin
block
viral
interact
cell
steric
hindranc
inde
cvn
solubl
lectin
griffithsin
activ
sever
emerg
virus
includ
vivo
efficaci
influenza
mani
emerg
virus
specif
receptor
either
unknown
suggest
receptor
still
controversi
howev
notabl
except
exampl
angiotensinconvert
enzym
function
receptor
sarscov
act
cellular
receptor
nipah
viru
niv
recent
tcell
immunoglobulin
mucin
domain
tim
shown
function
receptor
ebov
mucos
epithelia
yet
clear
whether
function
true
receptor
attach
factor
whether
like
play
major
role
vivo
due
restrict
express
howev
possibl
target
antivir
may
protect
import
cellular
target
reduc
pathogenesi
univers
receptor
filovirus
appear
cholesterol
transport
present
late
endosom
membran
unusu
circumst
first
recogn
incid
specif
receptor
interact
occur
within
cell
rather
plasma
membran
antagon
virusreceptor
interact
obviou
antivir
strategi
valid
maraviroc
receptor
antagonist
prove
success
hiv
inhibitor
pocket
groov
viral
glycoprotein
requir
receptor
recognit
may
ideal
small
molecul
specif
bind
although
may
difficult
small
molecul
inhibit
larg
protein
come
togeth
thu
peptid
antibodi
solubl
protein
therapeut
may
provid
like
rout
direct
receptor
bind
antagon
howev
sever
small
molecul
capabl
inhibit
interact
suggest
exampl
emodin
compound
identifi
chines
medicin
herb
screen
sarscov
demonstr
abil
inhibit
sarscov
protein
bind
protein
well
sproteinmedi
pseudoviru
infect
vero
cell
howev
caution
requir
term
attribut
mechan
thorough
studi
complet
initi
report
inhibit
receptor
interact
hiv
inhibitor
may
actual
act
indirect
mechan
bind
viral
glycoprotein
prevent
subsequ
conform
chang
requir
effici
bind
receptor
mediat
membran
fusion
although
receptor
antagonist
obviou
except
would
less
ideal
target
receptor
antagon
due
possibl
effect
natur
function
cellular
protein
howev
least
one
molecul
benzylpiperazin
adamantan
diamidederiv
compound
identifi
target
directli
inhibit
ebov
interact
receptor
henc
infect
assum
target
result
excess
cellular
toxic
may
thu
repres
excit
prospect
ebov
treatment
major
virus
follow
initi
attach
viru
cell
surfac
whether
attach
factor
specif
receptor
engag
specif
signal
traffick
event
occur
deliv
viru
late
endosom
typic
rout
viral
intern
includ
clathrinmedi
endocytosi
caveolar
lipid
raft
mediat
endocytosi
macropinocytosi
often
multipl
mechan
suggest
singl
viru
exampl
although
ebov
report
enter
clathrinmedi
endocytosi
via
caveoli
entri
filament
particl
import
cell
type
macrophag
thought
predominantli
occur
macropinocytosi
possibl
via
atyp
macropinocyt
pathway
target
intern
pro
con
antivir
strategi
like
target
import
cellular
function
toxic
side
effect
howev
possibl
multipl
pathway
exist
cell
specif
mechan
block
short
treatment
window
minim
effect
would
allow
treatment
acut
infect
hemorrhag
fever
death
like
altern
upsid
target
cellular
function
possibl
produc
broadspectrum
antivir
capabl
inhibit
larg
number
emerg
virus
depend
mechan
entri
cell
inde
panel
compound
chlorpromazin
avail
inhibit
variou
pathway
intern
function
effici
block
infect
exampl
studi
macropinocytosi
use
ebov
well
morpholog
similar
viruslik
particl
show
inhibitor
macropinocytosi
ctbpbar
actindepolymer
agent
cytochalasin
na
h
ion
exchang
inhibitor
eipa
pkc
inhibitor
staurosporin
reduc
infect
entri
mani
compound
also
shown
target
niv
entri
despit
viru
larg
phindepend
suggest
possibl
drug
target
may
broadspectrum
least
subset
emerg
virus
howev
compound
current
formul
unlik
use
antivir
even
though
alreadi
clinic
use
exampl
concentr
drug
chloroquin
chlorpromazin
requir
clinic
antivir
benefit
phdepend
virus
virus
requir
intern
like
significantli
higher
plasma
level
major
side
effect
would
note
howev
exampl
highlight
potenti
target
particular
pathway
antivir
treatment
overlook
somewhat
specif
target
intervent
may
signal
event
requir
order
trigger
intern
traffick
correct
cellular
destin
kinas
cell
signal
pathway
play
import
regulatori
role
multipl
cellular
activ
includ
cell
growth
migrat
surviv
vesicular
traffick
recent
pathway
implic
regul
cellular
entri
ebov
viru
inhibitor
wortmannin
block
ebov
viral
entri
dosedepend
manner
result
suggest
pathway
could
target
drug
intervent
toxic
issu
manag
particularli
good
avenu
research
given
inhibitor
alreadi
pursu
given
role
pathway
play
tumor
growth
late
endosom
lysosom
ebov
gp
sequenti
proteolyt
cleav
aciddepend
cystein
proteas
cathepsin
b
lesser
extent
l
catb
catl
respect
remov
heavili
glycosyl
nterminu
gp
expos
receptor
bind
domain
cleavag
event
probabl
destabil
prefus
complex
gp
allow
sequenti
conform
chang
requir
gp
occur
henc
membran
fusion
proceed
ebov
zair
ebolaviru
togeth
relat
speci
tai
forest
ebolaviru
bundibugyo
ebolaviru
strongli
depend
catb
convers
sudan
reston
speci
well
marv
depend
catb
rather
requir
yet
unidentifi
proteas
least
four
coronavirus
includ
sarscov
share
similar
entri
pathway
ebov
although
virus
catl
predominantli
requir
entri
cell
line
case
sarscov
sever
solubl
membranebound
proteas
substitut
catl
particularli
airway
cell
catl
also
play
import
role
process
envelop
glycoprotein
niv
hendra
virus
instanc
proteolysi
occur
recycl
protein
cell
surfac
infect
produc
cell
rather
viral
entri
filo
henipaand
lesser
extent
coronavirus
gener
inhibitor
cystein
proteas
specif
catb
catl
inhibitor
proven
highli
effect
block
infect
vitro
due
virus
depend
proteas
glycoprotein
activ
exampl
one
previou
studi
identifi
also
known
calpain
inhibitor
iii
zvalphecho
effici
inhibitor
catl
sarscov
entri
inhibitor
cell
line
anoth
studi
identifi
smallmolecul
oxocarbaz
catl
inhibitor
block
sarscov
ebov
pseudoviru
entri
human
cell
fact
inhibitor
effici
block
ebov
despit
potent
catl
compar
catb
vitro
highlight
common
theme
mani
inhibitor
less
specif
cellular
assay
may
actual
advantag
given
width
proteas
specif
demonstr
ebov
catb
catl
inhibitor
still
inhibit
speci
ebov
marv
inhibitor
escap
mutant
gener
case
catbinhibitor
resist
ebov
envelop
viru
longer
depend
catb
catl
still
requir
unidentifi
endosom
proteas
activ
possibl
activ
util
marv
fact
cathepsin
inhibitor
appear
lack
specif
also
open
possibl
compound
proteas
inhibitor
may
act
dualact
antivir
abl
target
viral
entri
viral
matur
inde
author
identifi
class
dipeptidyl
epoxyketon
molecul
tabl
abl
target
coronaviru
entri
inhibit
sarscovencod
proteas
probabl
best
target
intervent
multistep
process
viral
entri
envelop
virus
step
activ
trigger
viral
glycoprotein
requir
mediat
membran
fusion
regardless
viral
system
viral
glycoprotein
undergo
signific
conform
rearrang
order
drive
process
fuse
viral
cellular
membran
leav
open
inhibit
sever
stage
small
molecul
peptid
antibodybas
therapi
receptor
engag
low
ph
environ
late
endosomeslysosom
predomin
trigger
conform
chang
viral
glycoprotein
viral
glycoprotein
filo
henipaand
coronavirus
resembl
canon
viral
glycoprotein
hiv
influenza
term
class
virus
fusion
machineri
exist
trimer
heterodim
consist
surfac
transmembran
tm
subunit
trimer
held
socal
metast
state
prime
fusion
requir
activ
energi
trigger
conform
chang
lead
final
postfus
conform
state
trigger
includ
receptor
bind
acid
ph
initi
conform
chang
expos
highli
hydrophob
fusion
peptid
abl
insert
target
membran
subsequ
tm
subunit
fold
back
allow
two
region
within
subunit
term
heptad
repeat
hr
interact
glycoprotein
trimer
come
togeth
form
sixhelix
bundl
format
stabl
structur
drive
fusion
two
membran
altern
class
ii
virus
alphaand
flavivirus
util
differ
mechan
order
mediat
membran
fusion
although
ultim
structur
look
somewhat
similar
form
hairpin
glycoprotein
drive
membran
fusion
pack
much
highli
order
icosahedr
structur
virion
surfac
present
homodim
case
flavivirus
acid
ph
trigger
rearrang
lead
format
homotrim
result
exposur
fusion
peptid
insert
target
membran
glycoprotein
fold
back
form
hairpin
draw
membran
togeth
although
case
sixhelix
bundl
form
sever
step
along
cascad
event
lead
membran
fusion
appeal
target
antivir
intervent
particularli
prevent
conform
chang
within
glycoprotein
exampl
describ
hiv
entri
inhibitor
alloster
inhibitor
trap
metast
protein
inact
state
would
excel
lead
candid
drug
downstream
initi
conform
chang
hr
interact
inhibit
would
prevent
final
conform
chang
lead
membran
fusion
occur
inde
prototyp
viral
fusion
inhibitor
enfuvirtid
peptid
correspond
domain
hiv
effici
inhibit
infect
prevent
complet
sixhelix
bundl
format
similarli
synthet
peptid
deriv
hr
result
inhibit
membran
fusion
step
viral
entri
number
emerg
virus
includ
henipavirus
filovirus
sarscov
mani
virus
undergo
conform
chang
requir
expos
hr
endosom
method
direct
peptid
intern
compart
includ
fuse
target
domain
hiv
tat
greatli
enhanc
potenc
conjug
cholesterol
influenza
hemagglutininderiv
peptid
success
target
peptid
endosom
site
viral
fusion
similarli
case
niv
ad
cholesterol
peptid
target
lipid
raft
microdomain
util
viru
entri
benzodiazepin
deriv
identifi
entri
inhibitor
ebov
marv
ht
compound
librari
util
hivebovgp
pseudotyp
virus
comput
mutat
studi
use
ebovgp
crystal
structur
suggest
hydrophob
pocket
close
interfac
surfac
subunit
term
tm
subunit
potenti
site
compound
bind
similarli
novel
group
small
molecul
relat
isoxazol
identifi
use
pseudotyp
screen
strategi
compound
also
show
select
inhibit
ebov
marvgpmedi
infect
human
cell
mechan
inhibit
famili
antiebov
compound
yet
fulli
elucid
possibl
molecul
prevent
conform
chang
membran
fusion
new
world
arenavirus
util
transferrin
receptor
receptor
fuse
aid
acid
ph
within
endosom
number
relat
compound
identifi
bind
pocket
viral
glycoprotein
arenavirus
compound
spectrum
inhibit
abl
broadli
inhibit
arenavirus
other
specif
fact
inhibitor
share
bind
site
also
suggest
common
mode
action
although
exact
natur
fulli
elucid
howev
like
smallmolecul
entri
inhibitor
target
viral
glycoprotein
appear
underli
mechan
inhibit
may
prevent
conform
chang
critic
glycoprotein
transit
metast
state
activ
one
somewhat
similarli
ebov
util
cholesterol
transport
late
endosom
dengu
requir
lipid
specif
endosom
bi
monoacylglycero
phosphat
effici
membran
fusion
depend
unlik
uniqu
dengu
may
repres
excel
target
broadspectrum
target
drug
design
good
exampl
promis
broadspectrum
antivir
compound
target
entri
envelop
virus
small
molecul
term
aryl
methyldien
rhodanin
deriv
identifi
ht
antiniv
entri
use
vesicular
stomat
virusbas
pseudovirus
compound
subsequ
prove
effect
inhibit
viral
entri
numer
envelop
virus
includ
influenza
hiv
filo
pox
arena
bunya
paramyxoand
flavivirus
specif
intercal
viral
lipid
membran
probabl
inhibit
viral
entri
step
viru
bind
possibl
affect
rigid
curvatur
lipid
membran
thu
prevent
effici
viruscellular
membran
fusion
type
inhibitor
repres
unexpect
target
reveal
larg
batch
ht
assay
use
pseudotyp
virus
exemplifi
new
compound
identifi
similar
mechan
action
older
drug
arbidol
arb
small
indolederiv
first
market
russia
influenza
treatment
russian
clinic
trial
report
demonstr
reduct
length
symptom
influenzainfect
patient
although
efficaci
studi
anim
fail
demonstr
reduct
influenza
lung
titer
lung
consolid
addit
influenza
b
arb
activ
vitro
number
envelop
nonenvelop
respiratori
virus
well
hcv
although
variou
mode
action
ascrib
arb
immun
modul
bind
influenza
hemagglutinin
appear
like
mechan
inhibit
abil
arb
integr
membran
via
interact
polar
head
group
phospholipid
like
broadspectrum
activ
arb
explain
abil
perturb
membran
fluiditi
flexibl
histor
mani
emerg
virus
neglect
term
research
partli
due
lack
fund
also
difficulti
obtain
reagent
safeti
concern
handl
potenti
biohazard
sampl
howev
mani
emerg
virus
least
theoret
potenti
bioweapon
research
virus
profit
government
invest
biodefens
last
year
controversi
clearli
direct
fund
away
area
obviou
medic
need
hereandnow
deni
huge
stride
made
understand
previous
underresearch
pathogen
thu
outlook
next
year
new
antivir
therapi
target
emerg
virus
excit
particular
vivo
efficaci
studi
initi
mani
lead
compound
identifi
last
year
unit
state
latest
round
fund
region
center
excel
biodefens
emerg
infecti
diseas
rapidli
approach
may
much
money
invest
area
begin
dissip
focus
approach
replac
somewhat
haphazard
unselect
attitud
fund
last
year
howev
dissuad
investig
novel
idea
screen
drug
target
promis
antivir
appli
fund
research
particular
warrant
less
popular
virus
lassa
chikungunya
virus
rel
neglect
actual
infect
larg
number
individu
everi
year
favor
virus
grab
public
imagin
unlik
ever
threat
terrorist
otherwis
antivir
drug
typic
target
singl
viru
make
expens
virtual
imposs
stockpil
antivir
abl
treat
possibl
emerg
virus
potenti
weapon
biothreat
anoth
drawback
high
specif
tradit
antivir
viru
rapidli
adapt
develop
drug
resist
due
accumul
mutat
howev
current
broadspectrum
antivir
less
prone
develop
drug
resist
side
effect
limit
potenc
expens
widespread
use
therefor
one
import
goal
antivir
therapi
becom
identif
broadspectrum
antivir
regard
target
viral
entri
discoveri
novel
small
molecul
valid
exercis
safe
rapid
ht
assay
exist
use
multipl
envelop
screen
assay
identifi
broadspectrum
inhibitor
intrigu
idea
new
luciferas
report
gene
three
unrel
envelop
one
time
could
includ
singl
well
altern
specif
cellular
function
identifi
util
subgroup
virus
particular
target
specif
screen
antivir
exampl
follow
identif
cathepsin
import
factor
entri
corona
filo
paramyxoand
retrovirus
other
screen
specif
librari
cathepsin
proteas
inhibitor
antivir
cellular
viral
target
pursu
specif
broadspectrum
inhibitor
chang
viru
mutat
exposur
new
reservoir
human
encroach
alter
human
suscept
coinfect
increas
world
travel
risk
factor
potenti
new
viral
pandem
aris
great
need
develop
antivir
fight
divers
emerg
viru
diseas
well
serv
potenti
biodefens
need
current
antivir
drug
typic
target
singl
viru
option
major
emerg
virus
broadspectrum
antivir
avail
limit
potenc
often
side
effect
articl
review
recent
advanc
antivir
target
viral
entri
emerg
virus
ebola
viru
sarscoronaviru
discuss
potenti
broadspectrum
antivir
strategi
tabl
summari
studi
antivir
target
viral
entri
